Activated Immune System in Patients with Huntington's Disease

Abstract Abnormalities of immune system compartments were determined in 12 patients with Huntington's disease (eight males, four females; age 42.4 ± 11.7 years) and 11 controls (7 males, 4 females; age 47.0 ± 12.0). All patients were free from infectious diseases. Serum concentrations of a panel of serum soluble markers of immune activation were investigated, namely neopterin, 55-kDa-type soluble tumor necrosis factor receptor (sTNF-R), interleukin-2-receptor (sIL-2R), kynurenine, tryptophan, immunoglobulins (Ig) A, M and G as well as routine laboratory tests. Compared to controls, we found significantly higher serum levels of IgA (p < 0.01), sTNF-R, sIL-2R, neopterin, and complement component C3 (all p < 0.05), and serum tryptophan was decreased (p < 0.001). Higher concentrations of circulating immune complexes, cardiolipin antibodies, IgM, neopterin and lower tryptophan were associated with loss of cognitive function as assessed by the minimental-test. Five patients died within 1 year after measurements were performed. In these patients IgM, circulating immune complexes and neopterin concentrations were higher compared to survivors and serum tryptophan was lower. The data indicate an activation of various immune system compartments in Huntington's disease and that systemic immunological alterations might be important in the course of the disease.

[1]  E. Werner,et al.  Simultaneous measurement of serum tryptophan and kynurenine by HPLC. , 1997, Clinical chemistry.

[2]  K. Jellinger,et al.  Increased serum neopterin concentrations in a patient with Creutzfeldt-Jakob disease. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[3]  G. Tilz,et al.  Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis , 1995, European journal of haematology.

[4]  P. Jenner.  Oxidative damage in neurodegenerative disease , 1994, The Lancet.

[5]  D. Fuchs,et al.  Cerebrospinal fluid neopterin concentrations in central nervous system infection. , 1993, The Journal of infectious diseases.

[6]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[7]  M. Demitrack,et al.  Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. , 1992, Brain : a journal of neurology.

[8]  M. Beal,et al.  Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? , 1992, Annals of neurology.

[9]  E. Werner,et al.  Endogenous release of interferon-gamma and diminished response of peripheral blood mononuclear cells to antigenic stimulation. , 1989, Immunology letters.

[10]  R. Schwarcz,et al.  Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia , 1988, Annals of neurology.

[11]  R. Aster,et al.  New approaches to an old problem , 1988 .

[12]  Joseph B. Martin.  Huntington's disease , 1984, Neurology.

[13]  W. Tourtellotte,et al.  Cellular immune responses in Huntington disease Specificity of brain antigenicity detected with Huntington disease lymphocytes , 1978, Neurology.

[14]  D. Fuchs,et al.  Neopterin Production and Tryptophan Degradation in Acute Lyme Neuroborreliosis Versus Late Lyme Encephalopathy , 1994, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[15]  D. Fuchs,et al.  Neopterin, biochemistry and clinical use as a marker for cellular immune reactions. , 1993, International archives of allergy and immunology.

[16]  J. Blass.  Pathophysiology of the Alzheimer's syndrome , 1993 .

[17]  E. Werner,et al.  Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. , 1990, Journal of acquired immune deficiency syndromes.